Rhenman & Partners Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.4M	Buy	43,485 +9,230	+27%	+$4.3M	2.4%	9
2025 Q4	$15.5M	Sell	34,255 -12,700	-27%	-$5.47M	1.45%	27
2025 Q3	$18.4M	Sell	46,955 -14,500	-24%	-$6.06M	2.04%	18
2025 Q2	$27.4M	Sell	61,455 -5,295	-8%	-$2.44M	3.46%	3
2025 Q1	$32.4M	Buy	66,750 +16,750	+34%	+$7.81M	3.72%	3
2024 Q4	$20.1M	Buy	50,000 +2,250	+5%	+$1.04M	2.07%	15
2024 Q3	$22.2M	Sell	47,750 -6,250	-12%	-$3M	1.8%	23
2024 Q2	$25.3M	Sell	54,000 -2,500	-4%	-$1.09M	2.43%	14
2024 Q1	$23.6M	Sell	56,500 -38,500	-41%	-$16.3M	2.24%	16
2023 Q4	$38.7M	Buy	95,000 +18,500	+24%	+$6.83M	3.86%	4
2023 Q3	$26.6M	Buy	76,500 +13,000	+20%	+$4.55M	2.87%	7
2023 Q2	$22.3M	Sell	63,500 -20,000	-24%	-$6.74M	2.36%	14
2023 Q1	$26.1M	Buy	83,500 +3,500	+4%	+$1.05M	2.86%	5
2022 Q4	$23.1M	Sell	80,000 -16,000	-17%	-$4.88M	2.41%	9
2022 Q3	$30M	Buy	96,000 +1,000	+1%	+$288K	3.14%	4
2022 Q2	$26.8M	Buy	95,000 +5,500	+6%	+$1.47M	3.04%	9
2022 Q1	$23.4M	Sell	89,500 -75,500	-46%	-$17.9M	2.3%	10
2021 Q4	$36.7M	Hold	165,000	–	–	2.44%	12
2021 Q3	$29.9M	Sell	165,000 -50,897	-24%	-$9.94M	2.1%	13
2021 Q2	$43.5M	Buy	215,897 +47,476	+28%	+$9.93M	2.95%	3
2021 Q1	$36.2M	Buy	168,421 +53,421	+46%	+$11.7M	2.52%	7
2020 Q4	$27.2M	Buy	115,000 +5,000	+5%	+$1.15M	2.22%	11
2020 Q3	$29.9M	Sell	110,000 -27,500	-20%	-$7.59M	2.66%	5
2020 Q2	$39.9M	Buy	137,500 +22,500	+20%	+$6.1M	4.31%	2
2020 Q1	$27.4M	Sell	115,000 -45,000	-28%	-$10.3M	3.83%	2
2019 Q4	$35M	Sell	160,000 -26,000	-14%	-$5.26M	3.84%	2
2019 Q3	$31.5M	Buy	186,000 +768	+0.4%	+$136K	3.95%	1
2019 Q2	$34M	Buy	185,232 +40,832	+28%	+$7.14M	3.74%	1
2019 Q1	$26.6M	Buy	144,400 +11,975	+9%	+$2.21M	3.11%	3
2018 Q4	$21.9M	Sell	132,425 -10,040	-7%	-$1.74M	2.51%	8
2018 Q3	$27.5M	Sell	142,465 -12,535	-8%	-$2.23M	2.75%	4
2018 Q2	$26.3M	Buy	155,000 +5,000	+3%	+$775K	2.7%	3
2018 Q1	$24.4M	Sell	150,000 -2,204	-1%	-$360K	3.01%	4
2017 Q4	$22.8M	Sell	152,204 -27,796	-15%	-$4.12M	3.08%	5
2017 Q3	$27.4M	Buy	180,000 +84,987	+89%	+$12.8M	3.49%	2
2017 Q2	$12.2M	Hold	95,013	–	–	1.76%	21
2017 Q1	$10.4M	Buy	95,013 +30,000	+46%	+$2.64M	1.65%	24
2016 Q4	$4.79M	Sell	65,013 -15,000	-19%	-$1.22M	0.92%	43
2016 Q3	$6.98M	Buy	80,013 +20,013	+33%	+$1.89M	1.11%	32
2016 Q2	$5.16M	Sell	60,000 -18,000	-23%	-$1.56M	0.92%	44
2016 Q1	$6.2M	Buy	78,000 +22,000	+39%	+$1.99M	1.23%	35
2015 Q4	$7.05M	Sell	56,000 -49,000	-47%	-$5.92M	1.07%	37
2015 Q3	$10.9M	Buy	105,000 +50,000	+91%	+$6.42M	1.74%	23
2015 Q2	$6.79M	Sell	55,000 -3,000	-5%	-$378K	0.82%	41
2015 Q1	$6.84M	Buy	58,000 +20,000	+53%	+$2.4M	1.15%	30
2014 Q4	$4.51M	Sell	38,000 -5,000	-12%	-$563K	1.31%	27
2014 Q3	$4.83M	Sell	43,000 -58,600	-58%	-$5.58M	1.41%	21
2014 Q2	$9.62M	Buy	+101,600	New	+$7.12M	2.85%	6

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Rhenman & Partners Asset Management's VRTX Position: Q1 2026 in Review

Rhenman & Partners Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 27% in Q1 2026, buying an estimated $4.3M and bringing the position to 43,485 shares worth $19.4M. The position accounts for 2.4% of the portfolio, ranked #9.

Rhenman & Partners Asset Management first reported a position in VRTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $43.5M in Q2 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Rhenman & Partners Asset Management held 43,485 shares of Vertex Pharmaceuticals worth $19.4M as of Q1 2026.
Rhenman & Partners Asset Management bought 9,230 Vertex Pharmaceuticals shares in Q1 2026, an estimated $4.3M.
Vertex Pharmaceuticals made up 2.4% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #9 holding.
Rhenman & Partners Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
Rhenman & Partners Asset Management's Vertex Pharmaceuticals position peaked at $43.5M in Q2 2021.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.